ONCY
Oncolytics Biotech, Inc.

7,326
Mkt Cap
$107.43M
Volume
481,108.00
52W High
$1.51
52W Low
$0.3258
PE Ratio
-3.53
ONCY Fundamentals
Price
$0.9931
Prev Close
$0.9984
Open
$0.9712
50D MA
$1.10
Beta
0.85
Avg. Volume
816,403.21
EPS (Annual)
-$0.3026
P/B
1,241.38
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance PR Newswire VANCOUVER, BC, Dec. 12, 2025 Issued on behalf...
PR Newswire·15h ago
News Placeholder
More News
News Placeholder
Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on...
Business Wire·3d ago
News Placeholder
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·10d ago
News Placeholder
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat...
MarketBeat·11d ago
News Placeholder
Oncolytics Biotech Provides Update on Special Meeting of Shareholders
Oncolytics Biotech Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special...
Business Wire·22d ago
News Placeholder
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at HC Wainwright lifted their FY2025 EPS estimates for Oncolytics Biotech in a research note issued on Monday, November 17th...
MarketBeat·23d ago
News Placeholder
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·24d ago
News Placeholder
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration...
Business Wire·24d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Oncolytics Biotech from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·27d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat·28d ago

Latest ONCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.